發送短信 : A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 _    _    _    _     _____     _____     ______  
| \  / || | || | ||  |__  //   |  ___||  /_   _// 
|  \/  || | || | ||    / //    | ||__    `-| |,-  
| .  . || | \\_/ ||   / //__   | ||__      | ||   
|_|\/|_||  \____//   /_____||  |_____||    |_||   
`-`  `-`    `---`    `-----`   `-----`     `-`'